Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7125123 | 0.90 | SMN1; SMN2 (0.45) | PPARGEPHX2 | |
| SCHEMBL5749823 | 0.85 | MEN1 (0.48) | PPARGEPHX2PPARAFFAR1 | |
| SCHEMBL5749682 | 0.83 | PPARG (0.44) | PPARGEPHX2NOS3NOS1NOS2 | |
| SCHEMBL5751624 | 0.83 | PPARG (0.44) | PPARGEPHX2NOS3NOS1NOS2 | |
| SCHEMBL8071452 | 0.82 | NOS3 (0.42) | PPARGNOS3NOS1NOS2PPARA | |
| SCHEMBL5755755 | 0.82 | PPARG (0.43) | PPARGEPHX2PPARAFFAR1KCNQ3 | |
| SCHEMBL5753730 | 0.81 | NOS3 (0.47) | PPARGEPHX2NOS3NOS1NOS2 | |
| SCHEMBL5750535 | 0.78 | PPARG (0.34) | PPARGEPHX2FFAR1NPSR1 | |
| SCHEMBL5753448 | 0.77 | CETP (0.37) | PPARGEPHX2PPARA | |
| SCHEMBL5751205 | 0.77 | PPARG (0.54) | PPARGEPHX2NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | PPARG 905/4885EPHX2 1434/4885NOS3 2157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.